epaminurad + C2406

Epaminurad + C2406 is an investigational combination therapy studied for its pharmacokinetic, pharmacodynamic, and drug-drug interaction profile in healthy volunteers. **Epaminurad** is a novel, potent, and selective inhibitor of human urate transporter 1 (hURAT1), developed to reduce serum uric acid levels by promoting uric acid excretion in the kidney, intended for the treatment of hyperuricemia and gout. The mechanism of action of **C2406** is not clearly described in available public information. The combination has undergone Phase 1 studies to assess safety, pharmacokinetics, pharmacodynamics, and drug-drug interactions[2][3].